Top

Published in:

Open Access 23-01-2023 | Radiotherapy | Research

LINC01004-SPI1 axis-activated SIGLEC9 in tumor-associated macrophages induces radioresistance and the formation of immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma

Authors: Fen Zhao, Hui Tian, Yungang Wang, Jianbo Zhang, Fang Liu, Lei Fu

Published in: Cancer Immunology, Immunotherapy | Issue 6/2023

Abstract

Radioresistance and immunosuppression remain the major obstacles in the anti-cancer treatments. This work studies the functions of sialic acid binding Ig like lectin 9 (SIGLEC9) and its related molecules in radioresistance and immunosuppression in esophageal squamous cell carcinoma (ESCC). The single-cell analysis showed that SIGLEC9 was mainly expressed on tumor-associated macrophages (TAMs). Monocytes-derived macrophages were co-cultured with ESCC cells and subjected to radiotherapy. High or low doses of radiotherapy induced SIGLEC9 upregulation and M2 polarization of TAMs. Artificial inhibition of SIGLEC9 in TAMs suppressed the radioresistance and immunosuppressive tumor microenvironment (TME) in the co-cultured ESCC cells. Upstream molecules of SIGLEC9 were predicted via bioinformatics. LINC01004 recruited Spi-1 proto-oncogene (SPI1) in nucleus of TAMs to induce transcriptional activation of SIGLEC9. SIGLEC9 interacted with mucin 1 (MUC1). MUC1 overexpression in ESCCs induced M2 skewing of TAMs, enhanced radioresistance and immunosuppression, and promoted nuclear translocation of β-catenin to suppress radiotherapy-induced ferroptosis of ESCC cells. These effects were blocked upon SIGLEC9 suppression. In vitro results were reproduced in the animal models with xenograft tumors. Taken together, this study demonstrates that the LINC01004-SPI1 axis-activated SIGLEC9 in TAMs induces radioresistance and the formation of immunosuppressive TME in ESCC.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Reichenbach ZW, Murray MG, Saxena R, Farkas D, Karassik EG, Klochkova A et al (2019) Clinical and translational advances in esophageal squamous cell carcinoma. Adv Cancer Res 144:95–135. https://doi.org/10.1016/bs.acr.2019.05.004CrossRefPubMed

van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084. https://doi.org/10.1056/NEJMoa1112088CrossRefPubMed

Zhang H, Si J, Yue J, Ma S (2021) The mechanisms and reversal strategies of tumor radioresistance in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 147(5):1275–1286. https://doi.org/10.1007/s00432-020-03493-3CrossRefPubMed

Barker HE, Paget JT, Khan AA, Harrington KJ (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15(7):409–425. https://doi.org/10.1038/nrc3958CrossRefPubMedPubMedCentral

Zheng Y, Chen Z, Han Y, Han L, Zou X, Zhou B et al (2020) Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat Commun 11(1):6268. https://doi.org/10.1038/s41467-020-20019-0CrossRefPubMedPubMedCentral

Fraschilla I, Pillai S (2017) Viewing Siglecs through the lens of tumor immunology. Immunol Rev 276(1):178–191. https://doi.org/10.1111/imr.12526CrossRefPubMedPubMedCentral

Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S et al (2018) Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest 128(11):4912–4923. https://doi.org/10.1172/JCI120612CrossRefPubMedPubMedCentral

Zheng Y, Ma X, Su D, Zhang Y, Yu L, Jiang F et al (2020) The roles of Siglec7 and Siglec9 on natural killer cells in virus infection and tumour progression. J Immunol Res 2020:6243819. https://doi.org/10.1155/2020/6243819CrossRefPubMedPubMedCentral

10.

Cassetta L, Pollard JW (2020) Tumor-associated macrophages. Curr Biol 30(6):R246–R248. https://doi.org/10.1016/j.cub.2020.01.031CrossRefPubMed

11.

Pan Y, Yu Y, Wang X, Zhang T (2020) Tumor-associated macrophages in tumor immunity. Front Immunol 11:583084. https://doi.org/10.3389/fimmu.2020.583084CrossRefPubMedPubMedCentral

12.

Zhang Y, Feng Z, Liu J, Li H, Su Q, Zhang J et al (2022) Polarization of tumor-associated macrophages by TLR7/8 conjugated radiosensitive peptide hydrogel for overcoming tumor radioresistance. Bioact Mater 16:359–371. https://doi.org/10.1016/j.bioactmat.2021.12.033CrossRefPubMedPubMedCentral

13.

Rodriguez E, Boelaars K, Brown K, Eveline Li RJ, Kruijssen L, Bruijns SCM et al (2021) Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nat Commun 12(1):1270. https://doi.org/10.1038/s41467-021-21550-4CrossRefPubMedPubMedCentral

14.

Bhatia R, Gautam SK, Cannon A, Thompson C, Hall BR, Aithal A et al (2019) Cancer-associated mucins: role in immune modulation and metastasis. Cancer Metastasis Rev 38(1–2):223–236. https://doi.org/10.1007/s10555-018-09775-0CrossRefPubMedPubMedCentral

15.

Lee DH, Choi S, Park Y, Jin HS (2021) Mucin1 and mucin16: therapeutic targets for cancer therapy. Pharmaceuticals (Basel). https://doi.org/10.3390/ph14101053CrossRefPubMedPubMedCentral

16.

Beatson R, Maurstad G, Picco G, Arulappu A, Coleman J, Wandell HH et al (2015) The breast cancer-associated glycoforms of MUC1, MUC1-Tn and sialyl-Tn, are expressed in COSMC wild-type cells and bind the C-type lectin MGL. PLoS One 10(5):e0125994. https://doi.org/10.1371/journal.pone.0125994CrossRefPubMedPubMedCentral

17.

Beatson R, Tajadura-Ortega V, Achkova D, Picco G, Tsourouktsoglou TD, Klausing S et al (2016) The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol 17(11):1273–1281. https://doi.org/10.1038/ni.3552CrossRefPubMedPubMedCentral

18.

Su J, Zhao Q, Zheng Z, Wang H, Bian C, Meng L et al (2022) Prospective application of ferroptosis in hypoxic cells for tumor radiotherapy. Antioxidants (Basel). https://doi.org/10.3390/antiox11050921CrossRefPubMedPubMedCentral

19.

Wang HT, Ju J, Wang SC, Zhang YH, Liu CY, Wang T et al (2022) Insights into ferroptosis, a novel target for the therapy of cancer. Front Oncol 12:812534. https://doi.org/10.3389/fonc.2022.812534CrossRefPubMedPubMedCentral

20.

Liang Z, Wu Q, Wang H, Tan J, Wang H, Gou Y et al (2022) Silencing of lncRNA MALAT1 facilitates erastin-induced ferroptosis in endometriosis through miR-145-5p/MUC1 signaling. Cell Death Discov 8(1):190. https://doi.org/10.1038/s41420-022-00975-wCrossRefPubMedPubMedCentral

21.

Tanida S, Akita K, Ishida A, Mori Y, Toda M, Inoue M et al (2013) Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of beta-catenin and subsequent cell growth. J Biol Chem 288(44):31842–31852. https://doi.org/10.1074/jbc.M113.471318CrossRefPubMedPubMedCentral

22.

Wang Y, Zhao G, Condello S, Huang H, Cardenas H, Tanner EJ et al (2021) Frizzled-7 identifies platinum-tolerant ovarian cancer cells susceptible to ferroptosis. Cancer Res 81(2):384–399. https://doi.org/10.1158/0008-5472.CAN-20-1488CrossRefPubMed

23.

Cassetta L, Noy R, Swierczak A, Sugano G, Smith H, Wiechmann L et al (2016) Isolation of mouse and human tumor-associated macrophages. Adv Exp Med Biol 899:211–229. https://doi.org/10.1007/978-3-319-26666-4_12CrossRefPubMedPubMedCentral

24.

Akkari L, Bowman RL, Tessier J, Klemm F, Handgraaf SM, de Groot M et al (2020) Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aaw7843CrossRefPubMed

25.

Pu Y, Ji Q (2022) Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression. Front Immunol 13:874589. https://doi.org/10.3389/fimmu.2022.874589CrossRefPubMedPubMedCentral

26.

Tao L, Wang X, Zhou Q (2020) Long noncoding RNA SNHG16 promotes the tumorigenicity of cervical cancer cells by recruiting transcriptional factor SPI1 to upregulate PARP9. Cell Biol Int 44(3):773–784. https://doi.org/10.1002/cbin.11272CrossRefPubMed

27.

Zuo F, Zhang Y, Li J, Yang S, Chen X (2021) Long noncoding RNA NR2F1-AS1 plays a carcinogenic role in gastric cancer by recruiting transcriptional factor SPI1 to upregulate ST8SIA1 expression. Bioengineered 12(2):12345–12356. https://doi.org/10.1080/21655979.2021.2001168CrossRefPubMedPubMedCentral

28.

Xu H, Feng Y, Kong W, Wang H, Feng Y, Zhen J et al (2022) High expression levels of SIGLEC9 indicate poor outcomes of glioma and correlate with immune cell infiltration. Front Oncol 12:878849. https://doi.org/10.3389/fonc.2022.878849CrossRefPubMedPubMedCentral

29.

Genard G, Lucas S, Michiels C (2017) Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies. Front Immunol 8:828. https://doi.org/10.3389/fimmu.2017.00828CrossRefPubMedPubMedCentral

30.

Lodermann B, Wunderlich R, Frey S, Schorn C, Stangl S, Rodel F et al (2012) Low dose ionising radiation leads to a NF-kappaB dependent decreased secretion of active IL-1beta by activated macrophages with a discontinuous dose-dependency. Int J Radiat Biol 88(10):727–734. https://doi.org/10.3109/09553002.2012.689464CrossRefPubMed

31.

Wunderlich R, Ernst A, Rodel F, Fietkau R, Ott O, Lauber K et al (2015) Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function. Clin Exp Immunol 179(1):50–61. https://doi.org/10.1111/cei.12344CrossRefPubMed

32.

Crittenden MR, Cottam B, Savage T, Nguyen C, Newell P, Gough MJ (2012) Expression of NF-kappaB p50 in tumor stroma limits the control of tumors by radiation therapy. PLoS One 7(6):e39295. https://doi.org/10.1371/journal.pone.0039295CrossRefPubMedPubMedCentral

33.

Kohchi C, Inagawa H, Nishizawa T, Soma G (2009) ROS and innate immunity. Anticancer Res 29(3):817–821PubMed

34.

Seifert L, Werba G, Tiwari S, Giao Ly NN, Nguy S, Alothman S et al (2016) Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tumors in mice. Gastroenterology 150(7):1659–1672. https://doi.org/10.1053/j.gastro.2016.02.070CrossRefPubMed

35.

Huang J, Chen W, Jie Z, Jiang M (2022) Comprehensive analysis of immune implications and prognostic value of SPI1 in gastric cancer. Front Oncol 12:820568. https://doi.org/10.3389/fonc.2022.820568CrossRefPubMedPubMedCentral

36.

McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H et al (1996) Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J 15(20):5647–5658CrossRefPubMedPubMedCentral

37.

Yao J, Duan L, Huang X, Liu J, Fan X, Xiao Z et al (2021) Development and validation of a prognostic gene signature correlated with M2 macrophage infiltration in esophageal squamous cell carcinoma. Front Oncol 11:769727. https://doi.org/10.3389/fonc.2021.769727CrossRefPubMedPubMedCentral

38.

Bhan A, Soleimani M, Mandal SS (2017) Long noncoding RNA and cancer: a new paradigm. Cancer Res 77(15):3965–3981. https://doi.org/10.1158/0008-5472.CAN-16-2634CrossRefPubMedPubMedCentral

39.

Liu QP, Lin JY, An P, Chen YY, Luan X, Zhang H (2021) LncRNAs in tumor microenvironment: the potential target for cancer treatment with natural compounds and chemical drugs. Biochem Pharmacol 193:114802. https://doi.org/10.1016/j.bcp.2021.114802CrossRefPubMed

40.

Chen Y, Li Z, Chen X, Zhang S (2021) Long non-coding RNAs: from disease code to drug role. Acta Pharm Sin B 11(2):340–354. https://doi.org/10.1016/j.apsb.2020.10.001CrossRefPubMed

41.

Kang Y, Hirano K, Suzuki N, Enomoto A, Morita A, Irimura T et al (2000) Increased expression after X-irradiation of MUC1 in cultured human colon carcinoma HT-29 cells. Jpn J Cancer Res 91(3):324–330. https://doi.org/10.1111/j.1349-7006.2000.tb00948.xCrossRefPubMedPubMedCentral

42.

Detappe A, Mathieu C, Jin C, Agius MP, Diringer MC, Tran VL et al (2020) Anti-MUC1-C antibody-conjugated nanoparticles potentiate the efficacy of fractionated radiation therapy. Int J Radiat Oncol Biol Phys 108(5):1380–1389. https://doi.org/10.1016/j.ijrobp.2020.06.069CrossRefPubMedPubMedCentral

43.

Gunda V, Souchek J, Abrego J, Shukla SK, Goode GD, Vernucci E et al (2017) MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer. Clin Cancer Res 23(19):5881–5891. https://doi.org/10.1158/1078-0432.CCR-17-1151CrossRefPubMedPubMedCentral

44.

Wang Y, Zheng L, Shang W, Yang Z, Li T, Liu F et al (2022) Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer. Cell Death Differ. https://doi.org/10.1038/s41418-022-01008-wCrossRefPubMedPubMedCentral

Title: LINC01004-SPI1 axis-activated SIGLEC9 in tumor-associated macrophages induces radioresistance and the formation of immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma
Authors: Fen Zhao
Hui Tian
Yungang Wang
Jianbo Zhang
Fang Liu
Lei Fu
Publication date: 23-01-2023
Publisher: Springer Berlin Heidelberg
Keyword: Radiotherapy
Published in: Cancer Immunology, Immunotherapy / Issue 6/2023
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-022-03364-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2023

Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate

CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer

Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment

Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer